AstraZeneca's rummage sale continues with $350M deal, its second in a week

6th November 2018 Uncategorised 0

After unveiling a big asset sale last week, AstraZeneca is at it again with an agreement to hand some allergy and asthma drug rights to Covis Pharma for $350 million. It’s the latest in a string of cash-generating deals that have drawn criticism from some analysts and AZ investors alike.

More: AstraZeneca's rummage sale continues with 0M deal, its second in a week
Source: fierce